Yazar "Oruc, Nevin" seçeneğine göre listele
Listeleniyor 1 - 20 / 40
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC(Aves, 2008) Oruc, Nevin; Lamb, Janette; Whitcomb, David C.; Sass, David A.Background/aims: Primary biliary cirrhosis is an autoimmune liver disease that is strongly influenced by poorly defined, complex genetic factors. Alterations of the renin-angiotensin. system have been implicated in the pathogenesis of various diseases. A deletion polymorphism of a 287-bp fragment of intron 16 of the angiotensin converting enzyme gene allele results in higher levels of circulating enzyme. Angiotensin converting enzyme deletion genotype has been linked to hypertension and sarcoidosis and has been reported to regulate liver fibrosis in HCV-mediated liver disease. We investigated the frequency of the Angiotensin converting enzyme gene insertion/deletion polymorphism in primary biliary cirrhosis patients. Methods: 52 biopsy-proven primary biliary cirrhosis patients and 98 healthy controls were evaluated. Angiotensin converting enzyme insertion/deletion polymorphism was detected by polymerase chain reaction amplification of a genomic DNA fragment on intron 16 of the angiotensin converting enzyme gene. Clinical phenotype of primary biliary cirrhosis was verified with positive anti-mitochondrial antibody or M2 antibody, demonstration of cholestatic liver enzymes, and staging of liver biopsy. The differences between these variables among different genotypes were noted. Results: There was no significant difference in. genotypes and allele frequency between the primary biliary cirrhosis group and controls. The D allele frequency was 54% in primary biliary cirrhosis cases and 55% in controls (p=ns). Furthermore, there was no significant difference in clinical features between patients with angiotensin converting enzyme-insertion, or insertion/deletion genotypes vs. patients with angiotensin converting enzyme-deletion genotype. Conclusions: In our limited sample, the angiotensin converting enzyme deletion genotype did not make a. significant contribution to the pathogenesis or progression of primary biliary cirrhosis.Öğe Anti-Inflammatory Effect of Crude Momordica charantia L. Extract on 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis Model in Rat and the Bioaccessibility of its Carotenoid Content(Mary Ann Liebert, Inc, 2020) Unal, Nalan Gulsen; Kozak, Ayseguel; Karakaya, Sibel; Oruc, Nevin; Barutcuoglu, Burcu; Aktan, Cagdas; Ozutemiz, Ahmet OmerMomordica charantia L., known as bitter melon (BM), is a plant that belongs to the family Cucurbitaceae. Aims of this study are to investigate the anti-inflammatory effect of crude BM extract on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis model in rat. It was also aimed to determine the content and bioaccessibility of carotenoids of BM. BM was purchased from local markets in Izmir, Turkey. Fruits of BM were lyophilized, powdered, and used in the experiment. Carotenoids were determined by high-performance liquid chromatography. To determine the bioaccessibility of beta-carotene, in vitro digestion was performed. Wistar albino rats were divided into four groups: group A (BM+TNBS), group B (BM), group C (TNBS), and group D (control). BM solution was given 300 mg/(kg center dot day) for 6 weeks orally. Colitis was induced by 0.25 mL of a solution containing 100 mg/kg 5% (w/v) TNBS in 50% ethanol (w/v) intrarectally after 6 weeks. After sacrification, macroscopic and microscopic evaluations were performed. Myeloperoxidase, cytokines levels (interleukin-17 [IL-17], TNF-alpha, and interleukin-10 [IL-10]) were measured in serum and colonic samples by ELISA test. Institutional Animal Ethics Committee approval was obtained. Total carotenoid content of BM was determined 11.7 mg/g dry weight as beta-carotene equivalents. Bioaccessibility of total carotenoids was determined as 2.1% with in vitro digestion. Pretreatment with crude BM extract significantly reduced weight loss, macroscopic, and microscopic colitis damages in colonic samples (P = .000), (P = .015), and (P = .026), respectively. Serum anti-inflammatory cytokine IL-10 increased significantly in both treatment groups (P = .000). BM is a rich source of carotenoids, but the bioaccessibility of its carotenoids is low. This study displays that BM has protective anti-inflammatory effects on TNBS-induced colitis.Öğe Association Between Pancreatic Intraductal Papillary Mucinous Neoplasms and Extrapancreatic Malignancies(Elsevier Science Inc, 2015) Marchegiani, Giovanni; Malleo, Giuseppe; D'Haese, Jan G.; Wenzel, Patrick; Keskin, Muharrem; Pugliese, Luigi; Borin, Alex; Benning, Valentina; Nilsson, Linda; Oruc, Nevin; Segersvard, Ralf; Friess, Helmut; Schmid, Roland; Lohr, Matthias; Maisonneuve, Patrick; Bassi, Claudio; Ceyhan, Gueralp O.; Salvia, Roberto; Del Chiaro, MarcoBACKGROUND & AIMS: The association between pancreatic intraductal papillary mucinous neoplasms (IPMNs) and extrapancreatic neoplasms (EPNs) is controversial. We performed a multicenter observational study to assess the incidence of EPNs after an IPMN diagnosis. METHODS: 1340 patients with IPMNs were evaluated from 2000 through 2013 at 4 academic institutions in Europe for development of EPN. To estimate the actual incidence of EPN, we excluded patients with an EPN previous or synchronous to the IPMN, and patients who had been followed for less than 12 months, resulting in a study population of 816 patients. The incidence of EPN was compared with sex-specific, age-adjusted European cancer statistics; the standardized incidence ratio (SIR), and the 5- and 10-year cumulative incidence rates were calculated. RESULTS: A total of 290/1340 patients had a history of EPN (prevalence of 21.6%). In this subgroup of patients, the IPMN was discovered incidentally in 241. Among the 816 patients included in the incidence analysis, 50 developed an EPN after a median time of 46 months from study enrollment. The incidence of any EPN was not greater in patients with than without IPMN with a SIR of 1.48 (95% confidence interval, 0.94-2.22) in males and of 1.39 (95% CI 0.90-2.05) in females. The 5-and 10-year cumulative incidence rates for development of EPN in patients with IPMN were 7.9% and 16.6% in men, and 3.4% and 23.1% in women. CONCLUSIONS: Patients with IPMN do not have a significantly higher incidence of EPNs than the general European population. It might not be necessary to screen patients with IPMN for EPN.Öğe Association Between Pancreatic Intraductal Papillary Mucinous Neoplasms and Extrapancreatic Malignancies(Elsevier Science Inc, 2015) Marchegiani, Giovanni; Malleo, Giuseppe; D'Haese, Jan G.; Wenzel, Patrick; Keskin, Muharrem; Pugliese, Luigi; Borin, Alex; Benning, Valentina; Nilsson, Linda; Oruc, Nevin; Segersvard, Ralf; Friess, Helmut; Schmid, Roland; Lohr, Matthias; Maisonneuve, Patrick; Bassi, Claudio; Ceyhan, Gueralp O.; Salvia, Roberto; Del Chiaro, MarcoBACKGROUND & AIMS: The association between pancreatic intraductal papillary mucinous neoplasms (IPMNs) and extrapancreatic neoplasms (EPNs) is controversial. We performed a multicenter observational study to assess the incidence of EPNs after an IPMN diagnosis. METHODS: 1340 patients with IPMNs were evaluated from 2000 through 2013 at 4 academic institutions in Europe for development of EPN. To estimate the actual incidence of EPN, we excluded patients with an EPN previous or synchronous to the IPMN, and patients who had been followed for less than 12 months, resulting in a study population of 816 patients. The incidence of EPN was compared with sex-specific, age-adjusted European cancer statistics; the standardized incidence ratio (SIR), and the 5- and 10-year cumulative incidence rates were calculated. RESULTS: A total of 290/1340 patients had a history of EPN (prevalence of 21.6%). In this subgroup of patients, the IPMN was discovered incidentally in 241. Among the 816 patients included in the incidence analysis, 50 developed an EPN after a median time of 46 months from study enrollment. The incidence of any EPN was not greater in patients with than without IPMN with a SIR of 1.48 (95% confidence interval, 0.94-2.22) in males and of 1.39 (95% CI 0.90-2.05) in females. The 5-and 10-year cumulative incidence rates for development of EPN in patients with IPMN were 7.9% and 16.6% in men, and 3.4% and 23.1% in women. CONCLUSIONS: Patients with IPMN do not have a significantly higher incidence of EPNs than the general European population. It might not be necessary to screen patients with IPMN for EPN.Öğe Association Between Pancreatic Intraductal Papillary Mucinous Neoplasms and Extrapancreatic Malignancies(Elsevier Science Inc, 2015) Marchegiani, Giovanni; Malleo, Giuseppe; D'Haese, Jan G.; Wenzel, Patrick; Keskin, Muharrem; Pugliese, Luigi; Borin, Alex; Benning, Valentina; Nilsson, Linda; Oruc, Nevin; Segersvard, Ralf; Friess, Helmut; Schmid, Roland; Lohr, Matthias; Maisonneuve, Patrick; Bassi, Claudio; Ceyhan, Gueralp O.; Salvia, Roberto; Del Chiaro, MarcoBACKGROUND & AIMS: The association between pancreatic intraductal papillary mucinous neoplasms (IPMNs) and extrapancreatic neoplasms (EPNs) is controversial. We performed a multicenter observational study to assess the incidence of EPNs after an IPMN diagnosis. METHODS: 1340 patients with IPMNs were evaluated from 2000 through 2013 at 4 academic institutions in Europe for development of EPN. To estimate the actual incidence of EPN, we excluded patients with an EPN previous or synchronous to the IPMN, and patients who had been followed for less than 12 months, resulting in a study population of 816 patients. The incidence of EPN was compared with sex-specific, age-adjusted European cancer statistics; the standardized incidence ratio (SIR), and the 5- and 10-year cumulative incidence rates were calculated. RESULTS: A total of 290/1340 patients had a history of EPN (prevalence of 21.6%). In this subgroup of patients, the IPMN was discovered incidentally in 241. Among the 816 patients included in the incidence analysis, 50 developed an EPN after a median time of 46 months from study enrollment. The incidence of any EPN was not greater in patients with than without IPMN with a SIR of 1.48 (95% confidence interval, 0.94-2.22) in males and of 1.39 (95% CI 0.90-2.05) in females. The 5-and 10-year cumulative incidence rates for development of EPN in patients with IPMN were 7.9% and 16.6% in men, and 3.4% and 23.1% in women. CONCLUSIONS: Patients with IPMN do not have a significantly higher incidence of EPNs than the general European population. It might not be necessary to screen patients with IPMN for EPN.Öğe Autoimmune Pancreatitis after a Seven-Year History of Suspicious Pancreatic Cancer(Karger, 2021) Ergin, Erhan; Oruc, Nevin; OEzuetemiz, OEmerIn this case report, we present a case of autoimmune pancreatitis (AIP) diagnosis in a patient after a 7-year history of suspicious pancreatic cancer. Kim's and Japanese criteria were used to diagnose AIP. Our case avoided undesirable invasive procedures and recovered thanks to the proper diagnosis and timely treatment with prednisone. Early and accurate diagnosis of AIP, in this case, had a significant impact on the treatment and prognosis process. (C) 2021 The Author(s) Published by S. Karger AG, BaselÖğe Celiac disease associated with B-cell lymphoma(Aves, 2010) Oruc, Nevin; Ozutemiz, Omer; Tekin, Fatih; Sezak, Murat; Tuncyurek, Muge; Krasinskas, Alyssa M.; Tombuloglu, MuratCeliac disease is a gluten-induced enteropathy controlled by gluten restriction. Celiac disease is occasionally associated with T-cell lymphoma. We report a case with celiac disease who presented with duodenal ulcer-like symptoms and endoscopic findings. The persistent symptoms despite a strict diet led to the suspicion of an associated malignancy. Intensive evaluation revealed a case with celiac disease associated with B-cell lymphoma. Although B-cell lymphoma is rare, it should be kept in mind especially in female patients with persistent symptoms and refractory celiac disease.Öğe Chronic Hepatitis B Infection Management During Long-Term Follow-Up of Chronic Lymphocytic Leukemia (CLL) Treated With Multiple Lines of Chemoimmunotherapy, Including Ibrutinib(Cig Media Group, Lp, 2023) Sevgili, Bahar; Güneş, Ajda; Soyer, Nur; Sahin, Fahri; Oruc, Nevin; Saydam, Güray[No abstract available]Öğe Circadian changes in Critical Flicker Frequency in Cirrhotics and its relation with Sleep Disturbances(Wiley-Blackwell, 2012) Gencdal, Genco; Gunsar, Fulya; Meral, Cenk Emre; Salman, Esin; Gursel, Berna; Oruc, Nevin; Karasu, Zeki; Ersoz, Galip; Akarca, Ulus S.Öğe Co-analysis of pancreatic cyst fluid carcinoembryonic antigen and glucose with novel cut-off levels better distinguishes between mucinous and non-mucinous neoplastic pancreatic cystic lesions(Sage Publications Inc, 2022) Barutcuoglu, Burcu; Oruc, Nevin; Ak, Gunes; Kucukokudan, Serdar; Aydin, Ahmet; Nart, Deniz; Harman, MustafaBackground Pancreatic cyst fluid analysis plays an important role in distinguishing between mucinous and non-mucinous cyst lesions. We aimed to compare the diagnostic performances of cyst fluid carcinoembryonic antigen (CEA), CA 19-9, and glucose in differentiating mucinous from non-mucinous neoplastic pancreatic cystic lesions (PCLs) and determine the best cut-off levels. Methods Patients' data were evaluated retrospectively. 102 patients' PCLs were grouped as non-neoplastic (n = 25), non-mucinous neoplastic (n = 20), mucinous neoplastic (n = 47) and pancreatic adenocarcinomas with cystic degeneration (n = 10); and CEA, CA 19-9, and glucose levels were compared. Receiver-operating characteristic analysis was performed, and the ideal cut-off values were determined. Results Cyst fluid CEA and CA 19-9, levels were significantly higher (P < 0.001, P < 0.001, respectively) and glucose levels were significantly lower (P = 0.001) in mucinous than in non-mucinous neoplastic PCLs. Area under curve with 95% confidence interval of CEA, glucose and CEA and glucose test combination was 0.939 (95% CI = 0.885-0.993, P = 0.001), 0.809 (95% CI = 0.695-0.924, P < 0.001) and 0.937 (95% CI = 0.879-0.995), respectively. CEA cut-offs to rule-in and rule-out mucinous neoplastic were 135.1 ng/mL (sensitivity = 62%, specificity = 94.7%) and 6.12 ng/mL (sensitivity = 94.1%, specificity = 80.4%), respectively. Glucose cut-off of 2.8 mmol/L was chosen both to rule-in and rule-out mucinous neoplastic PCLs (sensitivity = 78%, specificity = 80%). Co-analysis of CEA and glucose to distinguish mucinous from non-mucinous neoplastic PCLs had sensitivity = 87.8%, specificity = 93.3%, and diagnostic accuracy = 89.3%. Conclusions We concluded that co-analysis of cyst fluid CEA (cut-off = 135.1 ng/mL) and glucose (cut-off = 2.8 mmol/L) at novel cut-offs had the best testing performance to rule-in mucinous neoplastic PCLs. To rule-out mucinous PCLs co-analysis of CEA (cut-off = 6.12 ng/mL) and glucose (cut-off = 2.8 mmol/L) added value to prediction.Öğe Common SPINK-1 genetic mutations do not predispose to Crohn disease(Tubitak Scientific & Technical Research Council Turkey, 2017) Oruc, Nevin; Osmanoglu, Necla; Aktan, Cagdas; Berdeli, Afig; Ozutemiz, Ahmet OmerÖğe Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease(Mexican Assoc Hepatology, 2009) Oruc, Nevin; Ozutemiz, Omer; Akarca, Ulus Salih; Berdeli, Afig; Ersoz, Galip; Gunsar, Fulya; Karasu, Zeki; Ilter, Tankut; Batur, YucelBackground: Non-alcoholic fatty liver disease (NAFLD) is common in obese and diabetics. Serine protease inhibitor Kazal-1 (SPINK-1) protein is highly expressed in the liver and adipose tissue of diabetic and obese suggesting its role in NAFLD. SPINK-1 also behaves as an acute phase reactant protein. Some genetic factors including the genetic variations in SPINK-1 protein have been linked to chronic pancreatitis and diabetes. We therefore hypothesized that SPINK-1 mutations might be a risk factor for the development of NAFLD. Methods: Liver biopsy proven fifty NAFLD cases (20 steatohepatitis, 30 diffuse fatty liver disease and 44 healthy controls were included to the study. Liver function tests were measured. Body mass index was calculated. Insulin resistance was determined by using a homeostasis model assessment (HOMA-IR). Ultrasound evaluation was performed for each subject. Common genetic mutations in the third exon of SPINK-1 gene were analyzed by direct sequencing method. Results: We found two cases with a SNP at N34S location in NAFLD group (allele frequency %4). One subject with diffuse fatty liver disease and other with liver cirrhosis due to NAFLD had N34S mutation. No SNPs were detected in healthy controls. In conclusions, in limited number of patients SPINK-1 mutations were not considered as a risk factor alone for NAFLD development.Öğe Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease(Turkish Soc Gastroenterology, 2009) Oruc, Nevin; Oezuetemiz, Oemer; Osmanoglu, Necla; Ilter, TankutBackground/aims: Procalcitonin and C-reactive protein are two acute-phase reactant proteins, although procalcitonin is a more specific marker for bacterial infections. Procalcitonin level might also be helpful to predict the disease activity of inflammatory bowel disease. This study aimed to compare the diagnostic value of serum procalcitonin and C-reactive protein as indicators of disease activity in inflammatory bowel disease. Methods: Patients admitted to the inflammatory bowel disease inpatient clinic with suspected inflammatory bowel disease who had not yet been treated with immunosuppressive treatments were included. Disease activity, white blood cell count, sedimentation rate, serum procalcitonin and C-reactive protein levels were evaluated in 45 newly diagnosed inflammatory bowel disease patients (9 Crohn's disease and 36 ulcerative colitis). Fifty healthy volunteers were analyzed as a control group. Results: Crohn's disease patients had higher procalcitonin and C-reactive protein levels than healthy controls (Procalcitonin: 0.143 +/- 0.081 us. 0.065 +/- 0.008 ng/ml, p<0.05; C-reactive protein: 29 +/- 7.5 vs. 2.9 +/- 0.5 mg/dl, p<0.001, respectively). Ulcerative colitis patients also had slightly higher procalcitonin levels and significantly higher C-reactive protein levels than controls (Procalcitonin: 0.107 +/- 0.042 ng/ml; C-reactive protein: 23 +/- 5.5 mg/dl). Two Crohn's disease patients had procalcitonin value above 1 ng/ml. Receiver operating characteristic curve analysis demonstrated that C-reactive protein is the best marker of disease activity in inflammatory bowel disease while procalcitonin has low sensitivity and specificity. Serum procalcitonin levels were highly correlated with serum C-reactive protein but no other disease activity parameters. Conclusions: Although still within normal ranges, procalcitonin levels were slightly elevated in Crohn's disease but not in ulcerative colitis patients compared to healthy controls. Serum C-reactive protein is a reliable marker for disease activity in inflammatory bowel disease. Procalcitonin has no diagnostic value in determining disease activity.Öğe Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with budd-chiari syndrome and/or portal vein thrombosis(Aves, 2015) Karakose, Suleyman; Oruc, Nevin; Zengin, Melia; Akarca, Ulus Salih; Ersoz, GalipBackground/Aims: The diagnosis of an underlying myeloproliferative neoplasm (MPN) is often problematic in patients with Budd Chiari syndrome (BCS) or portal vein thrombosis (PVT). This study aimed to assess the diagnostic value of the JAK2 gene V617F gain-of-function mutation for MPN in splanchnic vein thrombosis patients. Materials and Methods: One hundred eleven patients (80 with PVT, 27 with BCS, and 4 with BCS and PVT) were investigated. The control group included 56 volunteers without any known diseases. LightCycler SNP genotyping was performed to detect the JAK2 V617F mutation in DNA extracted from peripheral blood. Results: The JAK2 V617F mutation was identified in six of 28 patients (21.4%) with idiopathic PVT or BCS and in eight of 45 patients (17.8%) with PVT or BCS secondary to a known prothrombotic factor, but in only one of 38 patients (2.6%) with PVT and cirrhosis (p=0.049). Conclusion: The JAK2 V617F mutation is a noninvasive molecular marker for occult MPNs and can be used for the diagnosis of latent MPNs presenting with thrombotic events. Analysis of JAK2 mutation in the patients with idiopathic PVT or BCS showed that 20% had latent MPNs. In addition to this JAK2 mutation, prothrombotic events were observed in a significant number of patients with splanchnic vein thrombosis. JAK2 gene analysis should be included in the research panel for BCS and PVT patients without cirrhosis.Öğe Disruption of HNF1 alpha binding site causes inherited severe unconjugated hyperbilirubinemia(Elsevier Science Bv, 2015) van Dijk, Remco; Mayayo-Peralta, Isabel; Aronson, Sem J.; Kattentidt-Mouravieva, Anja A.; van der Mark, Vincent A.; de Knegt, Rob; Oruc, Nevin; Beuers, Ulrich; Bosma, Piter J.Crigler-Najjar syndrome presents as severe unconjugated hyper-bilirubinemia and is characteristically caused by a mutation in the UGT1A1 gene, encoding the enzyme responsible for bilirubin glucuronidation. Here we present a patient with Crigler-Najjar syndrome with a completely normal UGT1A1 coding region. Instead, a homozygous 3 nucleotide insertion in the UGT1A1 promoter was identified that interrupts the HNF1 alpha binding site. This mutation results in almost complete abolishment of UGT1A1 promoter activity and prevents the induction of UGT1A1 expression by the liver nuclear receptors CAR and PXR, explaining the lack of a phenobarbital response in this patient. Although animal studies have revealed the importance of HNF1 alpha for normal liver function, this case provides the first clinical proof that mutations in its binding site indeed result in severe liver pathology stressing the importance of promoter sequence analysis. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.Öğe Diurnal changes of critical flicker frequency in patients with liver cirrhosis and their relationship with sleep disturbances(Elsevier Science Inc, 2014) Gencdal, Genco; Gunsar, Fulya; Meral, Cenk Emre; Salman, Esin; Gursel, Berna; Oruc, Nevin; Karasu, Zeki; Ersoz, Galip; Akarca, Ulus S.Background: We aimed to measure the diurnal changes of critical flicker frequency in healthy subjects and cirrhotic patients and to investigate their relationship with sleep disturbance. Methods: Cirrhotic patients and healthy volunteers were included. All groups completed the Pittsburgh Sleep Quality Index and a simple sleep questionnaire. Sleep disturbance was defined as a Pittsburgh Sleep Quality Index score of >5. Critical flicker frequency was measured twice a day to detect diurnal abnormalities. Results: Overall, 59 cirrhotic patients (54.2% males, Mean Age 59 +/- 11 years) and 18 controls (39.9% males, Mean Age 58 +/- 9 years) were included. Sleep disturbances were more common in cirrhotics (66.1%) than controls (38.9%, p < 0.05). In cirrhotics, the critical flicker frequency was not related to decompensation. The nocturnal values were higher than the morning values in cirrhotics (64.4%), but not in controls (p < 0.0001). Additionally, sleep disturbances were more common in cirrhotics who had higher nocturnal values (p < 0.05). Conclusions: Changes in the diurnal critical flicker frequency were observed in cirrhotics but not in controls. Sleep disturbances in cirrhotics appear to be associated with deviations of the diurnal rhythm of critical flicker frequency rather than with clinical parameters such as the clinical stages of cirrhosis and the Model For End-Stage Liver Disease and Child-Pugh scores. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.Öğe Effect of microemulsion formulation on biodistribution of Tc-99m-Aprotinin in acute pancreatitis models induced rats(Taylor & Francis Ltd, 2016) Ilem-Ozdemir, Derya; Ustundag-Okur, Neslihan; Senyigit, Zeynep Ay; Oruc, Nevin; Asikoglu, Makbule; Ozutemiz, Omer; Karasulu, H. YesimBackground: Aprotinin is a monomeric globular polypeptide, which derived from bovine lung tissue and theoretically attractive molecule in ameliorating the effects of acute pancreatitis. Acute pancreatitis is an inflammatory condition of the pancreas that is painful and at times deadly. Over the following two decades Aprotinin therapeutic potential on pancreatitis is proven experimentally, its clinical therapeutic success is limited due to low targeting to pancreas. Objective: The aim of this study was to evaluate the biodistribution of Technetium-(99m)(Tc-99m)Aprotinin solution (Tc-99m-Aprotinin-S) and Tc-99m-Aprotinin loaded microemulsion, which was prepared for the aim of treatment for acute pancreatitis. Method: Aprotinin was radiolabeled with Tc-99m. Radiochemical purity was determined with radioactive thin layer chromatography studies. Tc-99m-Aprotinin-S and Tc-99m-Aprotinin loaded microemulsion (Tc-99m-Aprotinin-M) was administered to acute edematous, severe necrotizing pancreatitis and air pouch model induced rats. Tissue distribution of Aprotinin was investigated with gamma scintigraphy and biodistribution studies. Results: Aprotinin was radiolabeled by Tc-99m with high radiochemical purity (95.430 +/- 0.946%). The complex was found to be stable at room temperature up to 6 h. Animal studies have shown that similar to that of other small proteins Aprotinin is accumulated primarily in the kidney. The scintigraphy and biodistribution studies showed that, while i. v. administration of (99m)TcAprotinin-S distributed mostly in kidneys and bladder, Tc-99m-Aprotinin-M, with droplet size of 64.550 +/- 3.217 nm, has high uptake in liver, spleen and pancreas. Conclusion: This might be concluding that microemulsions may be suggested as promising formulations for selectively targeting Aprotinin to pancreas inflammation.Öğe Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up(Termedia Publishing House Ltd, 2017) Yalcin, Suayib; Bayram, Fahri; Erdamar, Sibel; Kucuk, Oztem; Oruc, Nevin; Coker, AhmetGastroenteropancreatic neuroendocrine tumors (GEPNETs) are a relatively rare, heterogeneous group of diseases in which important advances have been observed in the diagnosis and treatment as well as in our understanding of the biology and genetics of the disease in recent years. Given the insufficient scientific data available on evidence-based management of GEPNETs and the differences in circumstances in individual countries, a multidisciplinary study group was established to provide guidelines for the management of GEPNETS. This study group consisted of a medical oncologist, endocrinologist, surgeon, pathologist, gastroenterologist, and a nuclear medicine specialist, who aimed to prepare a practical guide in the light of existing scientific data and international guidelines, to be used in common clinical practice.Öğe Giant Esophageal Lipoma Presenting with Gastroesophageal Reflux Symptoms(Medical Univ Press, 2013) Yapali, Suna; Oruc, Nevin; Harman, Mustafa; Aydin, AhmetÖğe Giant Esophageal Lipoma Presenting with Gastroesophageal Reflux Symptoms(Medical Univ Press, 2013) Yapali, Suna; Oruc, Nevin; Harman, Mustafa; Aydin, Ahmet
